Search Results - "Dotor, Emma"

microRNA expression profile in stage III colorectal cancer: Circulating miR-18a and miR-29a as promising biomarkers by VEGA, ANNA BRUNET, PERICAY, CARLES, MOYA, IRENE, FERRER, ANNA, DOTOR, EMMA, PISA, ALEYDIS, CASALOTS, ÀLEX, SERRA-ARACIL, XAVIER, OLIVA, JOAN-CARLES, RUIZ, ANNA, SAIGÍ, EUGENI

“…Biomarkers that can facilitate disease detection, staging and prediction of outcome are highly desirable to improve survival and to help determine optimized…”
Get full text

Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment by DOTOR, Emma, CUATRECASES, Miriam, DE OCA, Javier, PEINADO, Miguel A, MORENO, Victor, GERMA, Josep Ramon, CAPELLD, Gabriel, VILLANUEVA, Alberto, MARTINEZ-INIESTA, Maria, NAVARRO, Matilde, VILARDELL, Felip, GUINO, Elisabeth, PAREJA, Laura, FIGUERAS, Agnés, MOLLEVI, David G, SERRANO, Teresa

“…The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal…”
Get full text

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study by Capdevila, Jaume, Teulé, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, García‐Carbonero, Rocío, Dotor, Emma, Matos, Ignacio, Custodio, Ana, Casanovas, Oriol, Salazar, Ramon

“…Background Antitumor activity of the combination of somatostatin analogues (SSAs) and the mammalian target of rapamycin (mTOR) inhibitor everolimus in patients…”
Get full text

Analysis and follow-up of the patients diagnosed with metastatic gastric adenocarcinoma in the Parc Taulí Hospital, Sabadell, between 2010 and 2013 by Ferrer, Marta, Pericay, Carles, Macias, Ismael, Dotor, Emma, Pisa, Aleydis, Saigí, Eugeni

“…Abstract only 169 Background: The primary endpoint of this study was to know the incidence and treatment of gastric carcinoma in our area. Other secondary…”
Get full text

Phase II study with docetaxel (D), cisplatin (C) and continuous capecitabine (X) schedule (DCX) in advanced gastric cancer (AGC): ML21085. Final results by Pericay, Carles, Losa, Ferran, Alfaro, Jordi, Cirera, Luis, Pisa, Aleydis, Salud, Antonieta, Falco, Esther, Casado, Esther, Nogue, Miquel, Dotor, Emma, Serra, Olbia, Fernandez, Julen, Saigí, Eugeni

“…Abstract only…”
Get full text

Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME) by Serra-Aracil, X., Pericay, C., Golda, T., Mora, L., Targarona, E., Delgado, S., Reina, A., Vallribera, F., Enriquez-Navascues, J. M., Serra-Pla, S., Garcia-Pacheco, J. C.

“…Purpose The standard treatment of rectal adenocarcinoma is total mesorectal excision (TME), in many cases requires a temporary or permanent stoma. TME is…”
Get full text

A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer by Navarro, Matilde, Dotor, Emma, Rivera, Fernando, Sánchez-Rovira, Pedro, Vega-Villegas, Maria Eugenia, Cervantes, Andrés, García, José Luis, Gallén, Manel, Aranda, Enrique

“…The aim of this study was to evaluate the efficacy and tolerance of preoperative chemoradiotherapy (CRT) with irinotecan (CPT-11) and 5-fluorouracil (5-FU) in…”
Get more information

Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD) by Carrato, Alfredo, Benavides, Manuel, Massuti Sureda, Bartolomeu, Longo, Federico, Garcia Alfonso, Pilar, Falco, Esther, Reboredo, Margarita, Gomez-España, M.Auxiliadora, Gallego, Javier, Vieitez, Jose M, Llayos@Iconcologia.Net, Laura, Salud, Antonia, Alonso, Vicente, Dotor, Emma, Gil, Silvia, Yuste, Ana, Pachon, Vanesa, Calvo, Aitana, Grande, Enrique, Aranda, Enrique

“…Abstract only…”
Get full text

Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs by Casanovas, Oriol, Capdevila, Jaume, Barriuso, Jorge, Teule, Alex, Castellano, Daniel E., Manzano, Jose Luis, Lopez, Carlos, Alonso, Vicente, Garcia Carbonero, Rocio, Dotor, Emma, Martinez, Alba, Salazar, Ramon

“…Abstract only 484 Background: Everolimus treatment is currently approved for a few tumor types and currently evaluated in several other malignancies, including…”
Get full text

Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD) by Carrato, Alfredo, Massuti Sureda, Bartolomeu, Benavides, Manuel, Guillén Ponce, Carmen, Falco, Esther, Garcia Alfonso, Pilar, Reboredo, Margarita, Cano, Maria Teresa, Gallego, Javier, Vieitez de Prado, Jose Maria, Layos, Laura, Salud, Antonia, Alonso, Vicente, Dotor, Emma, Yuste, Ana, Gil, Silvia, Ferreiro Monteagudo, Reyes, Fernandez Rodriguez, Teresa, Grande, Enrique, Aranda, Enrique

“…Abstract only…”
Get full text

Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD) by Grande, Enrique, Guillen-Ponce, Carmen, Vieitez de Prado, Jose Maria, Reboredo, Margarita, Duran, Gema, Massuti Sureda, Bartolomeu, Layos, Laura, Salud, Antonia, Falco, Esther, Alonso, Vicente, Garcia Alfonso, Pilar, Ortiz, Maria Jose, Sastre, Javier, Rivera, Fernando, Gallego, Javier, Robles, Luis, Gonzalez Astorga, Beatriz, Dotor, Emma, Carrato, Alfredo, Aranda, Enrique

“…Abstract only…”
Get full text

P-0202 Expression Profile of Mirnas in Stage III Colorectal Tumours: Overexpressed Mirnas As Potential Circulating Biomarkers by Brunet, Anna, Pericay, Carles, Moya, Irene, Dotor, Emma, Pisa, Aleydis, Casalots, Alex, Serra-Aracil, Xavier, Joan, Carles Oliva, Ruiz, Anna, Saigí, Eugeni

Get full text

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity by Borràs, Emma, Dotor, Emma, Arcusa, Angels, Gamundi, Maria J, Hernan, Imma, de Sousa Dias, Miguel, Mañé, Begoña, Agúndez, José A G, Blanca, Miguel, Carballo, Miguel

“…Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with life-threatening toxicity following exposure to the…”
Get full text

Synchronous isolated adrenal metastasis from rectum adenocarcinoma by Bonfill, Teresa, Dotor, Emma, Darnell, Anna, Casalots, Àlex, Bombardó, Jordi, Saigí, Eugeni, Pericay, Carles

Get full text

Extravasation of oxaliplatin: an infrequent and irritant toxicity by Pericay, Carles, López, Anna, Soler, Joan Ramón, Bonfill, Teresa, Dotor, Emma, Saigí, Eugeni

“…Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to…”
Get full text

1st National Meeting of Multidisciplinary Work in Oncogeriatrics: expert consensus document by Antonio, Maite, Saldaña, Juana, Formiga, Francesc, Lozano, Alicia, González-Barboteo, Jesús, Fernández, Paz, Arias, Fernando, Arribas, Lorena, Barbero, Elisabeth, Bescós, María del Mar, Boya, Maria Jesús, Bueso, Pilar, Casas, Ana, Dotor, Emma, Fort, Eduard, García-Alfonso, Pilar, Herruzo, Ismael, Llonch, Mireia, Morlans, Germà, Murillo, Maria Teresa, Ossola, Gustavo, Peiró, Inma, Saiz, Fabiola, Sanz, Javier, Serra, José Antonio, Trelis, Jordi, Yuste, Antonio

“…On 2nd of June 2011 the Institut Català d' Oncologia l'Hospitalet--Hospital Duran i Reynals hosted the first Meeting of Multidisciplinary Work in…”
Get full text

1.a Reunión Nacional de Trabajo Multidisciplinar en Oncogeriatría: documento de consenso by Antonio, Maite, Saldaña, Juana, Formiga, Francesc, Lozano, Alicia, González-Barboteo, Jesús, Fernández, Paz, Arias, Fernando, Arribas, Lorena, Barbero, Elisabeth, Bescós, María del Mar, Boya, Maria Jesús, Bueso, Pilar, Casas, Ana, Dotor, Emma, Fort, Eduard, García-Alfonso, Pilar, Herruzo, Ismael, Llonch, Mireia, Morlans, Germà, Murillo, Maria Teresa, Ossola, Gustavo, Peiró, Inma, Saiz, Fabiola, Sanz, Javier, Serra, José Antonio, Trelis, Jordi, Yuste, Antonio

“…Resumen El pasado día 2 de junio de 2011 el Institut Català d’Oncologia l’Hospitalet-Hospital Duran i Reynals acogió la primera Reunión de Trabajo…”
Get full text

Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer by Pericay Pijaume, Carles, Escudero Emperador, Pilar, Bastús Piulats, Román, Campos Cervera, Juan Manuel, Esquerdo Galiana, Gaspar, Gallén Castillo, Manuel, Alfaro Gamero, Jordi, Dotor Navarro, Emma, Pisa Gatell, Aleydis, Guasch Jordán, Inmaculada, Saigí Grau, Eugeni

“…Aim Advanced pancreatic cancer has a bad prognosis, with a median overall survival (OS) no longer than 4–6 months. Since the end of last century, monotherapy…”
Get full text